Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$9.92 USD
+0.42 (4.42%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $9.78 -0.14 (-1.41%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Redhill Biopharma Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 6 | 36 | 38 | 30 | 48 |
Receivables | 3 | 35 | 32 | 29 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 11 | 15 | 7 | 2 |
Other Current Assets | 3 | 4 | 5 | 6 | 2 |
Total Current Assets | 16 | 86 | 89 | 71 | 53 |
Net Property & Equipment | 0 | 1 | 1 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 6 | 66 | 72 | 88 | 17 |
Deposits & Other Assets | 0 | 0 | 16 | 16 | 0 |
Total Assets | 23 | 159 | 181 | 180 | 74 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 12 | 12 | 4 |
Current Portion Long-Term Debt | 0 | 115 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 18 | 21 | 24 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 59 | 47 | 36 | 0 |
Total Current Liabilities | 19 | 197 | 81 | 73 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 84 | 81 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 3 | 5 | 8 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 21 | 207 | 172 | 166 | 14 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 21 | 3 | 2 | 1 | 1 |
Capital Surplus | 388 | 383 | 375 | 293 | 267 |
Retained Earnings | -408 | -434 | -368 | -280 | -208 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2 | -48 | 9 | 14 | 60 |
Total Liabilities & Shareholder's Equity | 23 | 159 | 181 | 180 | 74 |
Total Common Equity | 2 | -48 | 9 | 14 | 60 |
Shares Outstanding | 0.70 | 0.10 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | 2.96 | -484.00 | 8.88 | 13.86 | 60.00 |
Fiscal Year End for Redhill Biopharma Ltd falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,991 | -99,999 | 6 | -99,999 | 16 |
Receivables | 1 | NA | 3 | NA | 3 |
Notes Receivable | NA | NA | 0 | NA | NA |
Inventories | 4 | NA | 4 | NA | 5 |
Other Current Assets | 3 | NA | 3 | NA | 3 |
Total Current Assets | 16 | NA | 16 | NA | 27 |
Net Property & Equipment | 0 | NA | 0 | NA | 0 |
Investments & Advances | NA | NA | 0 | NA | NA |
Other Non-Current Assets | NA | NA | 0 | NA | NA |
Deferred Charges | NA | NA | 0 | NA | NA |
Intangibles | 6 | NA | 6 | NA | 6 |
Deposits & Other Assets | 0 | NA | 0 | NA | 0 |
Total Assets | 22 | NA | 23 | NA | 35 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | NA | NA |
Accounts Payable | 2 | NA | 3 | NA | 3 |
Current Portion Long-Term Debt | NA | NA | 0 | NA | NA |
Current Portion Capital Leases | NA | NA | 0 | NA | NA |
Accrued Expenses | 4 | NA | 5 | NA | 7 |
Income Taxes Payable | NA | NA | 0 | NA | NA |
Other Current Liabilities | 15 | NA | 11 | NA | 16 |
Total Current Liabilities | 21 | NA | 19 | NA | 28 |
Mortgages | NA | NA | 0 | NA | NA |
Deferred Taxes/Income | NA | NA | 0 | NA | NA |
Convertible Debt | NA | NA | 0 | NA | NA |
Long-Term Debt | NA | NA | 0 | NA | NA |
Non-Current Capital Leases | NA | NA | 0 | NA | NA |
Other Non-Current Liabilities | 1 | 1 | NA | 2 | |
Minority Interest (Liabilities) | NA | NA | 0 | NA | NA |
Total Liabilities | 22 | NA | 21 | NA | 32 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | NA | NA |
Common Stock (Par) | 35 | NA | 21 | NA | 5 |
Capital Surplus | 375 | NA | 388 | NA | 381 |
Retained Earnings | -410 | NA | -408 | NA | -382 |
Other Equity | NA | NA | 0 | NA | NA |
Treasury Stock | NA | NA | 0 | NA | NA |
Total Shareholder's Equity | 0 | NA | 2 | NA | 3 |
Total Liabilities & Shareholder's Equity | 22 | NA | 23 | NA | 35 |
Total Common Equity | 99,999 | 0 | 2 | 0 | 100,002 |
Shares Outstanding | 1.10 | 1.10 | 0.70 | 0.40 | 0.20 |
Book Value Per Share | 90,908.24 | 0.00 | 2.96 | 0.00 | 500,012.35 |